Clinical trials: Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Iressa/Docetaxel in Non-Small-Cell Lung Cancer
Patients will receive 250 mg Iressa by mouth daily each day while on this study. Patients will also receive docetaxel 30 mg/m2 by by vein (IV) on day 1 weekly for the first 3 weeks of each course of therapy.
- Trial name
- NCT00048087
- Testing
- ZD1839, Docetaxel
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Non-Small-Cell Lung Cancer
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors.
- Conditions
- Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma
- Trial name
- NCT05355701
- Testing
- PF-07799933, binimetinib, cetuximab
- Where
- 40 sites in United States, Canada and 1 more
- Volunteers
- 103 people
- Sponsor
- Pfizer
NSCLC (Advanced Non-small Cell Lung Cancer)
A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This is a Randomized, Double-Blind, Multicenter, Phase II/III Study to Evaluate HLX37 (Recombinant Human Anti-PD-L1 and Anti-VEGF Bispecific Antibody) in Combination with Chemotherapy Versus Pembrolizumab in Combination with…
- Trial name
- NCT07865910
- Testing
- Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion)
- Where
- 16 sites in China
- Volunteers
- 1,438 people
- Sponsor
- Shanghai Henlius Biotech
Advanced Endstage Solid Carcinomas in Adults
CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors
To assess the anti-tumor activity of CAP7.1 based on the observed objective response rate and rate of disease stabilization, as defined by the below primary and secondary endpoints, in patients with Non-Small Cell Lung Carcinoma…
- Trial name
- CAP7-1 (NCT02094560)
- Testing
- CAP7.1
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- CellAct Pharma GmbH
Lung Cancer
Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)
Multinational, multi-center medical record review to describe the treatment patterns, clinical outcomes, and EGFR / T790M testing practices in EGFR-mutated advanced NSCLC patients receiving first-line EGFR TKI therapy in Europe.
- Trial name
- REFLECT (NCT04031898)
- Testing
- Non Interventional
- Where
- Bulgaria
- Volunteers
- 896 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Efficacy of Re-challenge With Immune-Checkpoints Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients: a Retrospective Observational Study
This is a multicentre, retrospective, national observational study aiming to describe clinical outcomes of advanced NSCLC patients that performed an ICP re-challenge during their history of disease.
- Trial name
- RE-CHALLENGE (NCT04069663)
- Testing
- No interventional study
- Where
- France
- Volunteers
- 144 people
- Sponsor
- University Hospital, Grenoble
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Lung Cancer
Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of rebeccamycin analogue is more effective in treating non-small cell lung…
- Trial name
- NCT00006017
- Testing
- becatecarin
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Case Comprehensive Cancer Center
Lung Cancer (NSCLC)
Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy
The second-line treatment options in clinical practice for immunotherapy progress are complex. Treatment strategies need to be selected based on different progression patterns.
- Trial name
- NCT07596524
- Testing
- Observation
- Where
- 3 sites in China
- Volunteers
- 300 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Non-Small Cell Lung Cancer
The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer
The purpose of this study is to compare the overall survival of patients with advanced non small cell lung cancer treated with docetaxel as single therapy versus docetaxel in combination with either gemcitabine or vinorelbine or…
- Trial name
- DISTAL-2 (NCT00345059)
- Testing
- docetaxel, vinorelbine, gemcitabine
- Where
- 24 sites in Italy
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute, Naples
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to…
- Trial name
- NCT06031688
- Testing
- Biospecimen Collection, Computed Tomography, Lymphoscintigraphy
- Where
- 278 sites in United States
- Volunteers
- 56 people
- Sponsor
- SWOG Cancer Research Network
Anxiety Disorder, Depression
Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
This trial is designed to test the efficacy of fluoxetine to improve patient's quality of life during chemotherapy. An innovative application of a selective serotonin reuptake inhibitor may modulate the effects of fatigue…
- Conditions
- Anxiety Disorder, Depression, Fatigue, Lung Cancer
- Trial name
- NCT00005850
- Testing
- cisplatin, fluoxetine, gemcitabine hydrochloride
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non Small Cell Lung Cancer
An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer
AZD9291 Early Access Program (EAP) was available in Taiwan during October 2015 to September 2016, a time period before the approval of AZD9291, to supply the unlicensed AZD9291 for the NSCLC patients who received at least one…
- Trial name
- NCT03457220
- Where
- 7 sites in Taiwan
- Volunteers
- 423 people
- Sponsor
- AstraZeneca
Lung Cancer
Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00653250
- Testing
- celecoxib, biopsy, therapeutic conventional surgery
- Volunteers
- 22 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
EGFR Mutation Positive Advanced Non-small-cell Lung Cancer
Gefitinib Long-term Survivor Study
The primary objective is to describe the genomic profile of long-term survivors, especially to find out potential genomic prognosis and/or predictive factors for gefitinib long-term efficacy as compared to rapid PD patients
- Trial name
- NCT02932345
- Where
- 14 sites in China
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Pancreatic Cancer, Osteosarcoma
BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
Forty patients with pancreatic cancer, sarcoma and carcinoma of breast will receive DNG64-CAR-V intravenously or intratumorally at a dose of 1-4 x 10e11 colony forming units (cfu) or equivalent 1.0-6.0 x 10e10 Vector Copies (VC)…
- Conditions
- Pancreatic Cancer, Osteosarcoma, MPNST (Malignant Peripheral Nerve Sheath Tumor), Chondrosarcoma
- Trial name
- NCT04091295
- Testing
- DNG64-CAR-V
- Where
- United States
- Sponsor
- Aveni Foundation
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Locally Advanced Lung Non-Small Cell Carcinoma
Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS)
The prospective study LOCATION MATTERS aims to investigate the radiation-induced damage to the heart and the cardiovascular system in patients treated with thoracic radiotherapy.
- Trial name
- LM (NCT06361784)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Non-small Cell Lung Cancer
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for…
- Trial name
- NCT00050960
- Testing
- bexarotene with carboplatin and paclitaxel, carboplatin and paclitaxel
- Where
- 154 sites in United States, Austria and 4 more
- Volunteers
- 612 people
- Sponsor
- Eisai Inc.
Radiation Pneumonitis
The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia
Radiation pneumonitis (RP) is a common complication of radiotherapy for thoracic tumors, and the incidence rate of grade 2 or above RP is 20% -40%; The use of antibiotics after secondary bacterial infection due to radiation…
- Trial name
- NCT06079931
- Testing
- Babaodan Capsule
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University